Evgen Pharma Share Discussion Threads

[mesquida] 14/8/2020 14:51

And in those days, jusjusjus the market closed at 3.30, but every other friday there was always a frantic rush to deal after hours for the new account so as to maximise the "free credit period". Memories !

[mesquida] 14/8/2020 14:41

Do keep up, moneymunch, do keep up !!!

[jusjusjus] 14/8/2020 14:37

we would never be back from Friday lunch drinks until way after market close, ohhh the good old days...

[the stigologist] 14/8/2020 14:36

I always found that Friday afternoon in the City my boss would come back from a boozy lunch with his mates and put on some mad trades especially at quiet times like August/Christmas

LOL

[carlisle44] 14/8/2020 14:28

What is driving this afternoon delight?

[bumpa33] 14/8/2020 14:19

never mind mm, where’s that perpetually whinging Toffeeman..?

[mesquida] 14/8/2020 14:17

Wakey, wakey , moneymunch , where are you ?

[prharry] 14/8/2020 14:15

Unable to buy. Glad I’ve got a chunk at 12p

[mesquida] 14/8/2020 14:14

14.67 bid for 100 now, you really wouldn't want to be etc.

[jusjusjus] 14/8/2020 14:14

can't get in!

[mesquida] 14/8/2020 14:04

You wouldn't want to be out of this over the weekend !!!

[aberloon2] 14/8/2020 14:03

Definitely something stirring...

[bumpa33] 14/8/2020 13:46

I’ve often wondered why this always seems to “wake up” in the afternoon? May be just coincidence.

[mesquida] 14/8/2020 13:43

And 13.67 bid for 100, looks promising, is it a coincidence that the US is just waking up ? !

[toffeeman] 14/8/2020 12:01

and again
and again
and again

yawn

[euclid5] 14/8/2020 11:10

Thanks for the details again

[moneymunch] 14/8/2020 10:53

Cheers Euclid, one can imagine Finncaps share price target for successful Covid-19 SFX-01 patient trials would be multiples of 25p, but in all honesty not too sure if the trials have started yet as Prof Chalmers Dundee website hasn't updated its status yet, but the following suggests Prof Dillon has started the evaluation of SFX-01 for NASH 1/4/20...Gl :-)

University of Dundee

Dillon, John

Professor of Hepatology and Gastroenterology , Professor

Clinical Professor (Teaching and Research) & Professor of Hepatology and Gastroenterology, Molecular and Clinical Medicine

 




Projects

Defining the Oxidative Stress-Related Mechanisms by which Activation of the Transcription Factor Nrf2 Arrests and Resolves Liver Fibrosis

Arthur, S., Dillon, J., Dinkova-Kostova, A., Hayes, J. & Henderson, C.

Medical Research Council

1/04/20 → 31/03/24

Project: Research



.....

5/12/19

Evgen Pharma (AIM: EVG) a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces it has entered into a Memorandum of Understanding with the The University of Dundee ("The University") to advance SFX-01 towards a clinical trial in non-alcoholic steatohepatitis ("NASH") and liver fibrosis. Evgen has agreed to supply SFX-01 to support a potential future clinical trial led by John Dillon, Professor of Hepatology and Gastrenterology in the University's School of Medicine.

With the assistance of Evgen, Professor Dillon will lead the process to secure appropriate grant funding and obtain clinical trial regulatory approval. The intention is to utilise advanced MRI scanning technology to investigate whether SFX-01 can reverse the hallmarks of NASH in a proof-of-concept clinical trial. Clinical data arising from a successful trial will support subsequent development, regulatory approval and commercialisation of SFX-01 in NASH and liver fibrosis. Evgen will be granted an option to the clinical data on fair commercial terms to enable it to advance development and commercialisation.

Non-alcoholic fatty liver disease ("NAFLD") is now regarded as the most common liver condition in the developed world, affecting up to 30% of the general population. NAFLD represents a spectrum of phenotypes ranging from simple steatosis (fatty infiltration), through NASH to cirrhosis. Approximately 30% of adults in the general population have NAFLD, and 10%-20% of these have NASH. Amongst patients with NASH, 20-30% are at risk of developing cirrhosis and subsequently dying from end-stage liver disease within 20 years. In view of the tens of thousands of individuals who are likely to develop NASH in the next decade, it is clear that this disease will represent a major burden to healthcare in the UK.

Professor John Dillon and colleagues have previously published research that showed that drug-induced activation of the Nrf2 pathway could reverse insulin resistance, suppress hepatic steatosis, and mitigated against NASH and liver fibrosis. On this basis, Professor John Dillon approached Evgen, the developer of SFX-01, a development stage drug that is known to activate the Nrf2 pathway and has demonstrated excellent safety and tolerability in previous clinical trials.

John Dillon, Professor of Hepatology and Gastrenterology at the University of Dundee's the School of Medicine said: "We are delighted that Evgen will support our plans to undertake a clinical trial on SFX-01 in patients with NASH. Oxidative stress is pivotal to the development of NASH and our research suggests that activation of the Nrf2 pathway, which in turn reduces oxidative stress, can reverse the pathology."

[euclid5] 14/8/2020 09:35

Thanks for that info Moneymunch - be interesting to see what PT the broker puts on SFX-01 for treating Covid 19 - but perhaps its to early stage for them to do that

[lovewinshatelosses] 14/8/2020 09:26

If this hits £2.50 or more, to make it a SNG style improvement, then that would be most pleasing. I am watching the share price action here with interest. With SNG, it was clear that the stock was getting dumped into fairly small rises, right up until results. It is one of the reasons why I only maintained a fairly small position there (compared to here and SBTX), as it just seemed bonkers to virtually fire sale stock when indications at the time pointed to a good chance of success, for that phase of proceedings. Braver investors than me ignored this and continued to pile in - and justifiably are enjoying far richer returns now. Perhaps we will see something similar here as and when/if things start heating up, as it did SNG. If it does, like SNG, I will top slice a small profit and let the rest run to wherever the end may be. GLA.

[bumpa33] 14/8/2020 09:01

one would hope they’re looking at an SNG style improvement.

And before anyone jumps on my case, I’m not comparing the two companies, just the share price

[aberloon2] 14/8/2020 08:57

Whoever has been buying all the EVG shares must be looking at a DDDD share price improvement...

[moneymunch] 14/8/2020 06:40

Good news stacking UP ......one would have thought that after 4 months, they would want a new CEO in place by the start of September which should add plenty of value and no doubt be the catalyst for a flow of positive newsflow thereafter........and every chance that Evgen could have a commercial partner waiting in the wings to advance SFX-01's undoubted potential over multiple disease targets imho...watch this space....the share price will be pushing UP past 15p plus and more to new highs in anticiapation imho....Gla ;-)

[bocker01] 13/8/2020 20:59

Also like the swiftness in responding to shareholder questions! Very open and very efficient!